Chronic erosive gastritis

Summary

Chronic erosive gastritis (MONDO:0022196) is a disease and 1 clinical trial. Top therapeutic interventions include sucralfate. A subtype of gastritis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	chronic erosive gastritis
Mondo ID	MONDO:0022196
SNOMED CT	63137003
UMLS	C0267145
MedGen	78626
Is cancer (heuristic)	no

Also known as: chronic erosive gastritis · idiopathic chronic, erosive gastritis · varioliform gastritis

Disease family

This is a subtype of gastritis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › stomach disorder › gastritis › chronic erosive gastritis

Related subtypes (15): gastroduodenal Crohn disease, viral gastritis, eosinophilic gastritis, bacterial gastritis, fungal gastritis, lymphocytic gastritis, necrotizing gastritis, granulomatous gastritis, gastroduodenitis, alcoholic gastritis, chronic gastritis, gastric mucosal hypertrophy, autoimmune gastritis, collagenous gastritis, pediatric collagenous gastritis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01284647	PHASE4	COMPLETED	A Study to Evaluate the Efficacy of Teprenone On Chinese Patients With Chronic Non-Atrophic Erosive Gastritis

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
SUCRALFATE	4	1
CHEMBL2367706	0	1